Factor IX Antibody (F9-1): sc-52800
- Factor IX Antibody (F9-1) is a mouse monoclonal IgG1 κ provided at 100 µg/ml
- raised against Factor IX of human origin
- recommended for detection of Factor IX of human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Factor IX Antibody (F9-1). This work is in progress.
QUICK LINKS
SEE ALSO...
Factor IX Antibody (F9-1) is a mouse monoclonal IgG1 antibody that detects coagulation factor IX in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Factor IX, also known as plasma thromboplastic component, plays a crucial role in the blood coagulation cascade, which is essential for hemostasis following tissue injury. Anti-Factor IX antibody (F9-1) recognizes this vitamin K-dependent serine protease, which is synthesized in the liver and circulates as an inactive precursor until activated by factor XIa-mediated proteolytic cleavage, resulting in factor IXa. The active form consists of a 145 amino acid light chain and a 236 amino acid catalytic heavy chain, which are linked by disulfide bonds. The proper functioning of factor IX is vital, as deficiencies or mutations in the Factor IX gene can lead to hemophilia B, a bleeding disorder characterized by an inability to form stable blood clots. Factor IX monoclonal antibody (F9-1) serves as an invaluable tool for researchers studying coagulation pathways and the molecular mechanisms underlying bleeding disorders, providing insights that could lead to improved therapeutic strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Factor IX Antibody (F9-1) References:
- The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa. | Aktimur, A., et al. 2003. J Biol Chem. 278: 7981-7. PMID: 12496253
- Factor IX variants improve gene therapy efficacy for hemophilia B. | Schuettrumpf, J., et al. 2005. Blood. 105: 2316-23. PMID: 15550487
- Factor IX complex for the correction of traumatic coagulopathy. | Joseph, B., et al. 2012. J Trauma Acute Care Surg. 72: 828-34. PMID: 22491593
- Evaluation of chromogenic factor IX assays by automated protocols. | Kershaw, GW., et al. 2018. Haemophilia. 24: 492-501. PMID: 29488668
- Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. | Preijers, T., et al. 2018. J Thromb Haemost. 16: 2196-2207. PMID: 30394056
- Identification of novel glycosylation events on human serum-derived factor IX. | Pegg, CL., et al. 2020. Glycoconj J. 37: 471-483. PMID: 32378017
- Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy. | Mülling, N., et al. 2021. Eur J Med Res. 26: 63. PMID: 34187575
- F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. | Branchini, A., et al. 2022. J Thromb Haemost. 20: 69-81. PMID: 34626083
- Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B. | Thompson, AR. 1977. J Clin Invest. 59: 900-10. PMID: 856873
- Factor IX activation by factor XIa proceeds without release of a free intermediate. | Wolberg, AS., et al. 1997. Biochemistry. 36: 4074-9. PMID: 9100000
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor IX Antibody (F9-1) | sc-52800 | 100 µg/ml | $316.00 |